JW Verret on Bending Money Rules for Biotech
Listen now
Description
Biotech firms have trouble getting reliable access to capital throughout the long, unpredictable development, testing, and approval process. While it’s in some ways a typical high risk, potentially high reward business, biotech can provide life-saving innovations when the success finally materializes.   J.W. Verret, GMU law school professor and member of the SEC’s investor advisory committee, has ideas to help biotech and other small-cap companies access the public and exempt markets more efficiently. Verret talks about why current securities regulations, like Reg A and Reg FD, hamper small-cap companies and hobble their search for liquidity. He discusses small changes, and better outreach from the SEC to small-cap firms, that could tip the scales and help match money with innovations that could improve lives.
More Episodes
The #MeToo movement has made us more aware of pervasive sexual harassment, but harassment based on every protected characteristic—including race, religion, age, and national origin—is pervasive and persistent. Former EEOC Commissioner Chai Feldblum, now a director of workplace culture consulting...
Published 02/19/20
Published 02/19/20
Cannabis is illegal under current federal law. But with attitudes—and state laws—changing, we could see federal legalization very soon. If that does happen, regulations will dictate how growers, makers, dispensers, and consumers comply with the resulting framework. What would those regulations...
Published 02/11/20